title: Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men.
abstract: Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men.
  
  
  BACKGROUND
  Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men.
  
  
  METHODS
  A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3alpha,17beta-diol-3glucuronide (3G) and androstane-3alpha,17beta-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound.
  
  
  RESULTS
  The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5% of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume.
  
  
  CONCLUSIONS
  Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.
authors.affiliation: Center for Bone Research, Departments of Internal Medicine and Geriatrics, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
authors.forename: Liesbeth
authors.initials: L
authors.lastname: Vandenput
authors.forename: Fernand
authors.initials: F
authors.lastname: Labrie
authors.forename: Dan
authors.initials: D
authors.lastname: Mellström
authors.forename: Charlotte
authors.initials: C
authors.lastname: Swanson
authors.forename: Thomas
authors.initials: T
authors.lastname: Knutsson
authors.forename: Ralph
authors.initials: R
authors.lastname: Peeker
authors.forename: Osten
authors.initials: O
authors.lastname: Ljunggren
authors.forename: Eric
authors.initials: E
authors.lastname: Orwoll
authors.forename: Anna L
authors.initials: AL
authors.lastname: Eriksson
authors.forename: Jan-Erik
authors.initials: JE
authors.lastname: Damber
authors.forename: Claes
authors.initials: C
authors.lastname: Ohlsson
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000728:Androgens / Q000097:blood*; D015519:Bone Density; D002853:Chromatography, Liquid; D008401:Gas Chromatography-Mass Spectrometry; D020719:Glucuronides / Q000097:blood*; D006801:Humans; D008297:Male; D011467:Prostate / Q000033:anatomy & histology*; D011863:Radioimmunoassay
chemical_list: D000728:Androgens; D020719:Glucuronides